Cambridge Antibody Technology Announces Grant of Antibody Expression Library Patents in US
MELBOURN, England, Sept. 19 /PRNewswire/ -- Cambridge Antibody Technology (Nasdaq: CATG; LSE: CAT) today announced the issue of four US patents covering antibody expression libraries -- the 'Huse/Lerner/Winter' patents. The patents are co-owned by the Medical Research Council, The Scripps Research Institute and Stratagene. Following the settlement of interference proceedings in June 1999, CAT is the sole exploiter of the intellectual property rights arising under the patents, subject to certain rights reserved by the co-owners and their pre-existing licensees.
The Huse/Lerner/Winter patents are entitled: ``Method for Producing Polymers Having a Preselected Activity'' (US 6,291,158 and US 6,291,159) and ``Method for Tapping the Immunological Repertoire'' (US 6,291,160 and US 6,291,161). The patents are generally directed to nucleic acid libraries for expression of functional immunoglobulin variable domains (or portions thereof) and methods of making such libraries.
CAT also announced the filing of an infringement suit alleging that MorphoSys AG and MorphoSys USA, Inc. infringe two of the Huse/Lerner/Winter patents (the '158 and '161 patents). The suit was filed in the United States District Court of Washington DC.
_____________
Wilder |
